Evaluation of Saliva as a Potential Alternative Sampling Matrix for Therapeutic Drug Monitoring of Levofloxacin in Patients with Multidrug-Resistant Tuberculosis-Reference-Cited by-同舟云学术

Evaluation of Saliva as a Potential Alternative Sampling Matrix for Therapeutic Drug Monitoring of Levofloxacin in Patients with Multidrug-Resistant Tuberculosis

Published:2019-05 Issue:5 Volume:63 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Ghimire Samiksha¹,Maharjan Bhagwan²,Jongedijk Erwin M.¹,Kosterink Jos G. W.¹,Ghimire Gokarna R.³,Touw Daan J.¹⁴,van der Werf Tjip S.⁵,Shrestha Bhabana²,Alffenaar Jan-Willem C.¹⁶

Affiliation:

1. University of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology, Groningen, The Netherlands

2. German Nepal TB Project, Nepal Anti-Tuberculosis Association, Kathmandu, Nepal

3. Government of Nepal, Ministry of Health and Population, Department of Health Services, National Tuberculosis Center, Kathmandu, Nepal

4. University of Groningen, Groningen Research Institute of Pharmacy, Department of Pharmacokinetics, Toxicology and Targeting, Groningen, The Netherlands

5. University of Groningen, University Medical Center Groningen, Infectious Diseases Service and Tuberculosis Unit, Groningen, The Netherlands

6. University of Sydney, Faculty of Medicine and Health, School of Pharmacy and Westmead Hospital, Sydney, Australia

Abstract

Saliva may be a useful alternative matrix for monitoring levofloxacin concentrations in multidrug-resistant tuberculosis (MDR-TB) patients. The objectives of this study were (i) to evaluate the correlation between plasma and salivary levofloxacin (Lfx) concentrations in MDR-TB patients and (ii) to gauge the possibility of using saliva as an alternative sampling matrix for therapeutic drug monitoring of Lfx in areas where TB is endemic.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.02379-18

Reference29 articles.

1. World Health Organization. 2018. WHO treatment guidelines for isoniazid-resistant tuberculosis. World Health Organization, Geneva, Switzerland.

2. Determination of plasma concentrations of levofloxacin by high performance liquid chromatography for use at a multidrug-resistant tuberculosis hospital in Tanzania

3. Pharmacokinetics of Levofloxacin in Multidrug- and Extensively Drug-Resistant Tuberculosis Patients

4. Multidrug-Resistant Tuberculosis Treatment Outcomes in Relation to Treatment and Initial Versus Acquired Second-Line Drug Resistance

5. Extensive Drug Resistance Acquired During Treatment of Multidrug-Resistant Tuberculosis

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Measurement of isoniazid in tuberculosis patients using finger sweat with creatinine normalisation: A controlled administration study;International Journal of Antimicrobial Agents;2024-08

2. Model-informed precision dosing: State of the art and future perspectives;Advanced Drug Delivery Reviews;2024-08

3. Can we Predict Drug Excretion into Saliva? A Systematic Review and Analysis of Physicochemical Properties;Clinical Pharmacokinetics;2024-07-15

4. Push forward LC-MS-based therapeutic drug monitoring and pharmacometabolomics for anti-tuberculosis precision dosing and comprehensive clinical management;Journal of Pharmaceutical Analysis;2024-01

5. Alternative Methods for Therapeutic Drug Monitoring and Dose Adjustment of Tuberculosis Treatment in Clinical Settings: A Systematic Review;Clinical Pharmacokinetics;2023-03